Evidence map›Paper›PMID 40717802›Full record

ArticleFrontiers in endocrinology2025

Risk factors for glucocorticoid induced osteoporosis in young adults.

Helena Florez, Josep Lluis Carrasco, Martina Barberá, José Hernández-Rodríguez, Africa Muxi, Anastasia Mocritcaia, Sergio Prieto-González, Maria C Cid, Ana Monegal, Núria Guañabens and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Helena FlorezMetabolic Bone Diseases Unit. Department of Rheumatology. Hospital Clinic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Josep Lluis CarrascoBiostatistics, Department of Basic Clinical Practice, University of Barcelona, Barcelona, Spain.
Martina BarberáBiostatistics, Department of Basic Clinical Practice, University of Barcelona, Barcelona, Spain.
José Hernández-RodríguezVasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Africa MuxiDepartment of Nuclear Medicine, Hospital Clinic, University of Barcelona, Barcelona, Spain.
Anastasia MocritcaiaMetabolic Bone Diseases Unit. Department of Rheumatology. Hospital Clinic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Sergio Prieto-GonzálezVasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Maria C CidVasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Ana MonegalMetabolic Bone Diseases Unit. Department of Rheumatology. Hospital Clinic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Núria GuañabensMetabolic Bone Diseases Unit. Department of Rheumatology. Hospital Clinic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Pilar PerisMetabolic Bone Diseases Unit. Department of Rheumatology. Hospital Clinic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Glucocorticoid-induced osteoporosis (GIOP) is one of the most frequent causes of secondary osteoporosis, especially in young subjects. However, current research and guidelines have scarcely addressed the therapeutic approach and risk factors for GIOP in adults less than 50 years of age. The aim of the study was to analyze if factors related to the development of glucocorticoid-induced osteoporosis (GIOP) and fragility fractures (FF) differ according to age. Methods: 127 patients on chronic glucocorticoid (GC) treatment were analyzed, including GC doses and duration, disease activity, FF, anthropometric data, bone metabolism parameters (including sex steroids), bone mineral density, trabecular bone score, and radiologic vertebral fractures; defining GIOP as densitometric osteoporosis and/or FF. Young subjects (<50 years old) were compared with those ≥50 years for risk factors of GIOP and FF. Results: GIOP prevalence was similar in both age groups: <50 (n=36) 44.4% Conclusions: More than 40% of young subjects on chronic GC therapy had GIOP. A higher BMI and disease activity and particularly, hypogonadism seem to be factors related to FF development in these subjects. Evaluation of these risk factors can improve the identification of young subjects at increased risk of fracture.

Indexed as

GlucocorticoidsOsteoporosisAdultAgedAge FactorsBody Mass IndexBone DensityFemaleHumansMaleMiddle AgedPrevalenceRisk FactorsYoung AdultGlucocorticoidsfragility fractureglucocorticoid-induced osteoporosishypogonadismrisk factorsyoung patients

Identifiers

PMID40717802
PMCPMC12289500

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.